FundsIndia research note about Natco Pharma.
Report is very concise, which I like, however it do not mention revlimid at all.
Market is Certain that revenue will drop after revlimid patent expiry. With New projects, if company able to maintain revenue, it may see P/E expansion.
Interesting time ahead!
Heads I win big and tales I do not lose much situation.
Natco FundsIndia.pdf (1.7 MB)
D: Invested
Any guess on what could be the right price?? Near term looks glim but 2 years down the line seems great.
In theory it is quite possible but you should consider the markets we are in and the valuations.
The valuations have low chances of getting more expensive than current rates (not considering results).
Also the companies who have high chances of posting remarkable growth, market is already discounting it at forward results (6 months to even 3 years)
So the window is very scarce in the SME segment at the moment. (Do note that few genuine SMEs will have some X times returns and some random operated SMEs will have unreal returns)
And be very cautious with the companies you choose in the current environment (if things went downhill, upto 80% fall can’t be ruled out)
For the Raymond Realty business, I hold a good position and I am thinking of having a track of certain growth variables. For now, from the available information from previous investor presentations, here are the details known to me:
With that information from ppts, I could derive Q1 FY25 nos for revenue and growth % YOY.
Armed with above information, I have made following tracking table:
I’ll be looking into next presentation and update the notes.
Sterling and Wilson Renewable Energy’s share price has recently dropped significantly, falling 23.5% over the past month. This decline is primarily attributed to the promoters selling a substantial stake in the company, which has raised concerns among investors about the company’s future prospects. On September 28, 2024, the promoters sold shares worth Rs 1 billion, with Shapoorji Pallonji holding a 12.7% stake and Khurshed Yazdi Daruvala holding 1.5% as of June 30, 2024.
The ongoing reduction of promoter holdings—from 69% in June 2023 to 52.9% by June 2024—has exacerbated investor anxiety, leading to further selling pressure. Promoters typically have insider knowledge of a company’s value, so their stake sales can signal a lack of confidence in future growth.
Despite these challenges, Sterling and Wilson is focusing on expanding its operations and maintaining a strong presence in both domestic and international markets. The company aims to achieve Rs 80 billion in revenue this fiscal year and is optimistic about growth in solar installations due to increasing demand for renewable energy and government initiatives.
The company’s financial health remains robust, with decreasing net debt and a growing operations and maintenance (O&M) portfolio, which is expected to provide stability over the next 12-18 months.
Thank you @bheeshma for the insight. I’ll follow the guidance.
I’ll be tracking these numbers going forward. I have put up following in my notes.
Once again, Thank you for patiently answering my queries and helping out!
what about the product spreads? How/where do you’ll track their product spreads?
I heard that phenol spreads bottomed out 2-3 months ago and so did the promoter bought.
And since a lot of capex is going to come live, i wanted to track the key raw materials and end products they use/produce.
Is it a red flag if a company has over ₹139 crores invested in stocks?
For Sep it’s not part of Top 15. Which means it has fallen below the 38.28 Mn volume of 15th ranked player Central Bank of India. Not a good sign. Market would like an explanation.
Read more at: Tata Power Seeking Bids For ₹21,000 Cr Order, Suzlon, Siemens In Fray: Report – Benzinga